［1］Siegel RL，Miller KD.Cancer statistics，2017［J］.Clin J Cancer，2017，67(1)：7-30.
[2]Chen W，Zheng R，Zeng H.The updated incidences and mortalities of major cancers in China，2011［J］.Chin J Cancer，2015，34(11)：502-507.
[3]Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015［J］.Cancer Clinicians，2016，66(2)：115-132.
[4]Thompson EW，Torri J，Sabol M，et al.Oncogene-induced basement membrane invasiveness in human mammary epithelial cells［J］.Clin Exp Metastasis，1994，12(3)：181-194.
[5]Luo Yulin，Cai Fenglin，Tan Haosheng，et al.Progress of epithelial mesenchymal transition in breast cancer related signaling pathways［J］.Int J Surg，2018，45(1)：56-61.［罗雨林，蔡凤林，谭好升，等.上皮间质转化在乳腺癌相关信号通路中的研究进展［J］.国际外科学杂志，2018，45(1)：56-61.］
[6]Ingthorsson S，Andersen K，Hilmarsdottir B，et al.HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR［J］.Oncogene，2016，35(32)：4244-4255.
[7]Muraoka RS，Dumont N，Ritter CA，et al.Blockade of TGF-beta inhibits mammary tumor cell viability，migration，and metastases［J］.J Clinical Investigation，2002，109(12)：1551-1559.
[8]Bui QT，Im JH，Jeong SB，et al.Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer［J］.Cancer Lett，2017，390：115-125.
[9]Wu ZQ，Li XY，Hu CY，et al.Canonical wnt signaling regulates slug activity and links epithelial-mesenchymal transition with epigenetic breast cancer 1，early onset (BRCA1) repression［J］.Proc Nat Acad Sci USA，2012，109(41)：16654-16659.
[10]Carmichael J.Advanced breast cancer：Investigational role of gemcitabine［J］.Eur J Cancer，1997，33(Suppl 1)：S27-30.
[11]Zhang Y，He L，Meng L，et al.Suppression of tumor-induced angiogenesis by taspine isolated from Radix et Rhizoma Leonticis and its mechanism of action in vitro［J］.Cancer Letters，2008，262(1)：103-113.
[12]Brown LF，Guidi AJ，Schnitt SJ，et al.Vascular stroma formation in carcinoma in situ，invasive carcinoma，and metastatic carcinoma of the breast［J］.Clin Cancer Research，1999，5(5)：1041-1056.
[13]Ahn GO.Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis：Role of bone marrow-derived myelomonocytic cells［J］.Cancer Cell，2008，13(3)：193-205.
[14]Benson CS，Babu SD，Radhakrishna S，et al.Expression of matrix metalloproteinases in human breast cancer tissues［J］.Dis Markers，2013，34(6)：395-405.
[15]Zhang Weiran，Zhang Bin.Progress on research of matrix metalloproteinases and epithelial-mesenchymal transition in breast cancer［J］.Chinese Journal of Clinical Oncol，2012，39(10)：753-756.［张伟然，张斌.基质金属蛋白酶与乳腺癌上皮间充质转化关系的研究进展［J］.中国肿瘤临床，2012，39(10)：753-756.］
[16]Lee S，Jilani SM，Nikolova GV，et al.Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors［J］.J Cell Biology，2005，169(4)：681-691.
[17]Nelson WJ，Nusse R.Convergence of Wnt，beta-catenin，and cadherin pathways［J］.Science，2004，303(5663)：1483-1487.
[18]Wang Z，Zhang H，Hou J，et al.Clinical implications of beta-catenin protein expression in breast cancer［J］.Int J Clin Exp Pathol，2015，8(11)：14989-14994.
[19]Cho KB，Cho MK，Lee WY.Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells［J］.Cancer Lett，2010，293(2)：230-239.
[20]Trimboli AJ，Fukino K，de Bruin A，et al.Direct evidence for epithelial-mesenchymal transitions in breast cancer［J］.Cancer Research，2008，68(3)：937-945.